Researchers have developed a method to screen large libraries of synthetic cyclic peptides for membrane permeability, a critical step in unlocking macrocyclic peptides as a viable drug modality. The approach, detailed in Genetic Engineering News, targets compounds that can enter cells to exert therapeutic effects, combining the specificity of biologics with the convenience of a pill.
The technique addresses a long-standing challenge in peptide drug development: most cyclic peptides are too large or polar to cross cell membranes. By screening at scale, the method identifies rare candidates that can passively diffuse into cells, potentially expanding the druggable target space beyond traditional small molecules.
The findings open avenues for designing oral macrocyclic drugs against intracellular targets, such as protein-protein interactions, which are often inaccessible to conventional therapies. No specific trial data or regulatory timelines were disclosed in the report.
While promising, the approach remains largely preclinical. Experts note that achieving both membrane permeability and target binding in vivo is complex, and many candidates may fail in later stages. The report highlights that the method is still in the validation phase, with no clinical candidates yet identified.
Investor impact is unclear at this stage, as no company or regulatory filing was named. The technology's significance lies in its potential to derisk a historically difficult drug class, but widespread adoption will require independent replication and integration into existing drug discovery pipelines.